Related Experiment Videos
Pathologic features of prostate cancer found at population-based screening with a four-year interval
R F Hoedemaeker1, T H van der Kwast, R Boer
1Department of Pathology, Erasmus University Rotterdam, The Netherlands. Hoedemaeker@path.fgg.eur.nl
Journal of the National Cancer Institute
|August 2, 2001
Summary
A 4-year interval for prostate-specific antigen (PSA) screening appears sufficient to detect curable prostate cancer, reducing the detection of aggressive tumors. This study suggests longer screening intervals may be viable for prostate cancer detection.
Area of Science:
- Urology
- Oncology
- Public Health
Background:
- Current prostate-specific antigen (PSA) screening frequency is 1 year, but optimal interval remains unknown.
- Investigating longer screening intervals to assess impact on curable prostate cancer detection.
Purpose of the Study:
- To determine if a 4-year screening interval compromises the detection of curable prostate cancer.
- To compare cancer detection rates and tumor characteristics between initial and follow-up PSA screenings.
Main Methods:
- A cohort of 4491 men aged 55-75 years participated in an initial PSA screening.
- Men were invited for a second screening 4 years later, with pathology findings compared.
- Statistical analysis of biopsy findings between the two screening rounds.
Main Results:
- Median cancer amount in biopsies decreased from 7.0 mm to 4.1 mm over 4 years (P=.001).
- Detection of high-grade (Gleason score ≥7) prostate cancer dropped from 36% to 16% (P<.001).
- Adverse prognostic features in detected cancers decreased significantly from 25% to 6% (P<.001).
Conclusions:
- A 4-year screening interval effectively detected most large prostate cancers with high PSA levels.
- This interval appears sufficient to limit the development of large tumors.
- Further research is needed to confirm if this interval yields a survival benefit.